With the limitations of a relatively small sample size of the primary 3D spheroid cultures, the current study represents a proof of concept that combined anti-AXL and anti-TGFβ treatments might represent a therapeutic option for selected molecular subgroups of CRC that deserves further investigation. The gene discussed is TGFB1; the disease is colorectal carcinoma.